Comparative Pharmacology

Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

Amino Acid Solution

Category C

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

Amino Acid Solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.

Amino acids serve as substrates for protein synthesis and intermediary metabolism; dextrose provides caloric replacement; electrolytes maintain acid-base and electrolyte balance.

Clinical Dosing

Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.

Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day administered as a continuous or intermittent infusion, providing 4.25% amino acids and 5% dextrose. Rate adjusted based on metabolic needs and tolerance.

Direct Interaction

None Documented